Resources for a Family of Diseases
  Uveitis Study Needs ParticipantsPatients, both male and female, between the ages of 18 and 25, with non-infectious acute anterior uveitis and any previous episodes of acute anterior ileitis occurring at least four weeks before starting the study are being invited to enroll in a safety and efficacy study of iontophoresis and dexamethasone phosphate to treat anterior uveitis. The study is being sponsored by EyeGate Pharmaceutical.
This is a randomized, double-masked exploratory study of four doses of iontophoretic delivery of dexamethasone phosphate ophthalmic solution in patients with non-infectious acute anterior segment uveitis. The current study will evaluate the safety, tolerability, and efficacy of the technology at the four dose levels to determine a safe, effective dose that is appropriate for future trials.
Five centers currently enrolling patients are located in Cambridge and Boston, MA; New York, NY; Norfolk, VA; and Columbus, OH.
For more information or to enroll, go to www.clinicaltrials.gov(study#NCT00694135); or contact Debbie Chmielewski at 887-334-0050 (a Texas number) or e-mail debbie.chmielewski@pleiad.com
Source: EyeGate Pharmaceuticals, Waltham, MA Autoimmune Diseases Association, InFocus, Vol. 16 No. 3, September 2008 726 1856 Print This Email This
|
Vasculitis Foundation Research Grant ProgramMedical ConsultantsVF medical consultants provide advice by telephone or e-mail to physicians who treat patients with Vasculitis.
|
About Vasculitis Foundation
The Vasculitis Foundation (VF) is the only international organization for patients with Vasculitis. Founded in 1986, VF provides patients and family members with practical information and coping strategies to live successfully with Vasculitis.
Mission: The Vasculitis Foundation supports and empowers patients through education, awareness and research. Learn more